DATATRAK worked with Bellicum to design a combined technology and services offering to assist in the progression of their oncology products throughout the FDA clinical trial process. As a biotherapeutics company, Bellicum needs to control data collection and management costs for their biological drug products from development through commercialization. The DATATRAK Enterprise pricing model and DATATRAK Clinical and Consulting Services' (DCCS) expertise were the ideal solution for Bellicum. The DATATRAK Enterprise pricing model allowed Bellicum to project their costs over the five year period of clinical trial execution, and with DCCS providing a full suite of professional services, Bellicum enjoys a single source vendor for their data needs.

"We are pleased to collaborate with DATATRAK on our clinical trial programs," said Tom Farrell, CEO of Bellicum. "This partnership will enable us to advance our two lead clinical development programs for patients with prostate cancer and patients undergoing a hematopoietic stem cell transplant."

"We are very excited about our new relationship with Bellicum," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "As biotechs are vital contributors in bringing new drugs to market and improving quality of life, we are happy to play a small part in the development of their new products."

The DATATRAK ONE Clinical Research Platform is an easy to use, cloud-based clinical enterprise solution that empowers Sponsors and CROs to efficiently design, deliver and manage clinical trials. From strategy and planning to resource management and study execution needs, clients manage their entire product portfolio in a single system with one username and password. DATATRAK's unified clinical enterprise solution consists of seven products: uCTMS, uDesign, uEDC, uIRT, uSafety, uTrain and uCDR.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing clinical applications of chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered. Bellicum's mission is to leverage this smart technology to bring safe, effective, innovative cell therapies to market for patients with serious and life threatening diseases. For more information, visit www.bellicum.com.

About DATATRAK

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on August 15, 2012 announcing its results for the three-month period ending June 30, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.